Abstract It is well known that small, randomized, controlled trials (RCTs) have limited validity. When comparing the results of meta-analyses with those of later large trials or with those of large trials removed from the metaanalyses, discrepancies were reported. This paper addresses two issues: (1) how measures of the uncertainty in costeffectiveness, i.e., cost-effectiveness acceptability curves (CEACs), and the expected value of perfect information (EVPI) are affected by the limited validity of small trials and (2) how to deal with this bias. To this end, the paper adopts a Bayesian approach. Using empirical estimates for the validity of small RCTs compared to larger RCTs, the probability of cost-effectiveness drops by almost 10 %, while the EVPI is three times higher. In conclusion, traditional CEACs and EVPI analyses based on (small) RCTs may need careful appraisal. Ignoring prior evidence on the validity of small-size trials leads to an underestimation of uncertainty in cost-effectiveness. For future economic analyses, it is important to incorporate aspects of uncertainty which are caused by flawed data on effectiveness.
Introduction
When assessing uncertainty in cost-effectiveness analyses, one needs to distinguish between different types of uncertainty such as structural, methodological, and parameter uncertainty [1] . Parameter uncertainty, which is the focus of this paper, refers to parameters with the greatest level of uncertainty such as those with the greatest influence on model outcomes, key clinical variables, or main cost drivers [1] . Among variables reflecting parameter uncertainty is data on clinical efficacy. In the case of smaller trials instead of larger ones, efficacy tends to be overestimated (small study effect) [2] . That is, evidence suggests that the smaller the underlying clinical trial is, the more likely it is that positive results will not be confirmed in a subsequent larger study [3] . Hence, the consideration of single small trials (i.e., trials with fewer than 100 patients per arm [4] ) or the inclusion of small studies in meta-analyses may affect the overall estimate of a treatment's effect [4, 5] .
Similar to the well-known problem of external validity that occurs when applying the results of RCTs to patients in a particular clinical setting or in routine practice [6] , the results of earlier trials may differ from those of later trials due to broad spectrum of patients used in these trials. Once an intervention has left behind its initial testing phase, it may be applied in less sick patients [7] . In addition, timelag, publication bias, methodological bias, and outcome reporting bias are often considered to be the main causes of early overestimation [2] .
When assessing parameter uncertainty in cost-effectiveness analyses, a cost-effectiveness acceptability curve (CEAC) can be constructed. The CEAC describes the probability that an intervention is cost-effective for a range of willingness to pay. An extension of the CEAC is the expected value of perfect information (EVPI) analysis, which measures the expected costs of uncertainty of a treatment decision. It takes into account parameter uncertainty and estimates the value of collecting additional information. It can be used by analysts to design further research studies as well as by policy makers to consider priorities for the adoption of medical technologies [8] [9] [10] [11] [12] .
While CEACs can have both a frequentist and Bayesian interpretation [13] [14] [15] , EVPI analysis is based on a Bayesian decision analytic framework [8, 16] (for details see appendix in supplementary material). While frequentists use confidence intervals or P values to measure the strength of the evidence in the data, Bayesian methods allow the construction of 'credible intervals' for parameters of interest [17] . A 95 % credible interval is an interval such that the true population parameter lies in the interval with a probability of 0.95 [17] . The Bayesian perspective allows one to explicitly combine prior beliefs and expert knowledge concerning underlying parameters with the observed data to obtain probability distributions of the parameters [17] .
Because CEACs and EVPI only reflect the data they are based on, their informative value for decision makers can be limited by flawed clinical data more often than expected. The purpose of this paper is therefore to show (1) that ignoring prior evidence on the validity of small-size trials leads to an underestimation of uncertainty in cost-effectiveness and (2) how to consider this prior evidence when calculating CEACs and EVPI.
Small study effect
Effectiveness data for CEACs/EVPI analyses are often based on large, randomized, controlled trials (RCTs), which have generally been considered the ''gold standard'' for the evaluation of medical interventions [18] . In cases where large RCTs are not available, CEACs/EVPI analyses are sometimes based on ''piggyback evaluations'' in which health-economic data are collected within an otherwise typical clinical or observational study with fewer than 200 patients [19] [20] [21] [22] [23] [24] [25] . Alternatively, CEACs/EVPI analyses may be based on economic models alongside a small single RCT [26] , on an indirect comparison of two drugs via placebo due to a lack of direct clinical data [27] , or on meta-analyses summarizing the results of several smaller trials [28] [29] [30] [31] [32] [33] . None of the above-mentioned trials had positive results later confirmed by a large RCT, and for some of them, later RCTs have even shown contradictory evidence.
An examination of the presence and extent of small study effects in meta-analyses on osteoarthritis treatment indicated that, on average, treatment effects were greater in small trials than in large trials, with a difference in effect sizes for a pain-related outcome of -0.21 (95 % confidence interval -0.34 to -0.08, P = 0.001) (see Fig. 1 ) [4] . While in almost 50 % of meta-analyses, the overall pooled estimate suggested a clinically relevant and significant benefit of treatment, analyses restricted to large trials yielded smaller non-significant estimates [4] .
Similarly, when comparing the results of meta-analyses with those of later large trials [3] or with those of large trials removed from the meta-analyses, discrepancies were reported [34, 35] . The degree of difference depends on how endpoints were defined and which method was used for the comparison. For example, substantial discrepancies between meta-analyses of large and small trials were reported when the variability of treatment effects among different trials was not considered (i.e., when using a fixedeffects model) [35] .
Application example
We present a hypothetical example to show how small study bias affects both CEACs and EVPI analyses and how this bias can be properly accounted for when conducting such analyses. Because both CEAC and net monetary benefit (NMB) rely on the size of the difference in effectiveness, we suggest using a sceptical prior based on the degree to which a small RCT result is assumed to overestimate the true effect. Such a correction factor can be obtained from the standardized effect size (treatment effect/standard deviation). The reason for choosing the standardized effect size is that in funnel plots of metaanalyses, treatment effects are usually plotted against their standard deviation. For our example, we obtained an estimate of the difference in effect size between smaller and larger trials (sceptical prior) by searching in PubMed with the terms ''small study effects'' and ''meta-analysis''. Based on 78 meta-analyses across a spectrum of diseases, the prior for the difference in effect size between smaller and larger trials is 0.54 (95 % confidence interval 0.42-0.65) [5] . Suppose a randomized trial with 50 patients per arm shows an incremental effect of 1.75 (standard error 0.5 Units), incremental costs of €1,800 (standard error €1,000), and no correlation between costs and effects. The willingness to pay per unit of effectiveness is €10,000. The standard approach to analysis, which ignores the bias inherent in small trials, yields a mean NMB of €15,700, standard deviation of €5,066, and a probability of CE of 99.9 %. Incorporating information on the extent of bias in small trials yields a posterior mean incremental effectiveness of 0.4 (95 % credible interval -0.6 to 1.41). As a result, the probability of CE drops to 65 % (see Fig. 2 ) and the NMB to €2,200.
Similarly, the use of data from small RCTs also leads to an underestimation of the EVPI, which can be estimated by multiplying the standard deviation with the loss function L (Á):
where r 0 is the standard deviation of the NMB, and L (Á) is the standard normal loss function, i.e., the expected number of lost units of effectiveness as a fraction of the standard deviation.
Based on the above data for a non-informative prior, the EVPI per patient would be €0 (€5,066 9 L[(€15,700 -€0)/€5,066]). When using the estimate of incremental effectiveness from a sceptical prior (i.e., 0.4 with 95 % credible interval -0.6 to 1.41), the EVPI per patient increases to €1,200 (€5,293 9 L[(€2,166 -€0)/€5,293]).
Both examples show that uncertainty captured by CEACs and EVPI calculations may be underestimated if large and recently conducted clinical trials are not available and data on effectiveness are based on small or early conducted trials.
Discussion
This paper recommends accounting for bias in small trials when calculating CEACs and EVPI using a Bayesian approach. The paper shows that ignoring such prior evidence leads to an overestimation of clinical effectiveness and an underestimation of uncertainty in cost-effectiveness.
Data on effectiveness should be based on large and recently conducted RCTs whenever possible, as they have been shown to be the most valid. If pooled data are taken, those based on larger meta-analyses (e.g., 1,000 patients or more) are more valid than data based on smaller metaanalyses [36] . However, even the use of large RCTs may have important disadvantages. First, large RCTs as defined either by sample size ([1,000 patients) [3, 34, 35] or power ([0.8) [35] do not entirely capture the quality of a trial's design and execution [18] . For example, trials with [1,000 patients may still be underpowered if the treatment effect is small but clinically significant [18] . Second, large RCTs may also be affected by the problem that in earlier trials, patients have higher baseline risks [7] , thus leading to an overestimation of effectiveness in clinical practice. And third, they may not be able to capture long-term adverse effects due to their limited time horizon.
To consider the limited validity of effectiveness data (due to small trials, meta-analyses of small trials, or artificial trial environment), a sceptical prior distribution could be used, as shown in this paper, for the CEAC and the EVPI analysis. That is, effectiveness data could be weighted with a factor reflecting the expected disagreement with large RCTs or real-world data. This would be in accordance with a Bayesian decision analytic framework where an analyst's belief is described a priori. If one is interested in a particular disease or a specific type of intervention with available evidence in that field, this evidence should be used. Otherwise, one could use pooled evidence across similar diseases for defining an appropriate prior.
A second recommendation would be to improve the reporting quality on efficacy data in cost-effectiveness analyses. We suggest that reporting of information about trial size becomes mandatory, particularly if cost-effectiveness analyses are based on synthesis-based estimates. We also recommend that authors of cost-effectiveness studies provide information about assessments of a small study bias if their study is based on a meta-analysis (i.e., present several well-established statistical and graphical methods [37] ).
To summarize, CEACs and EVPI analyses computed with effectiveness data based on meta-analyses or RCTs with insufficient power may oversimplify a complex issue. Decision makers should be aware of the hazard of being misled by unrealistic assumptions that are concealed in input parameters used for economic analyses.
